Soleno Therapeutics/$SLNO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Soleno Therapeutics

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Ticker

$SLNO
Primary listing

Industry

Biotechnology

Employees

115

SLNO Metrics

BasicAdvanced
$4.5B
-
-$4.65
-2.67
-

Bulls say / Bears say

FDA approval of VYKAT XR for treating hyperphagia in Prader-Willi syndrome positions Soleno Therapeutics as a leader in this niche market, potentially driving significant revenue growth. (globenewswire.com)
The European Medicines Agency's validation of the Marketing Authorization Application for DCCR tablets indicates potential expansion into European markets, broadening the company's revenue base. (globenewswire.com)
Analyst upgrades and increased institutional investment reflect growing confidence in Soleno's strategic direction and product pipeline. (etfdailynews.com)
The Phase 3 DESTINY PWS trial failed to achieve statistical significance on the primary hyperphagia endpoint, raising concerns about the robustness of efficacy data. (panabee.com)
Soleno reported a $176 million net loss in 2024, with an accumulated deficit of $452 million, indicating financial instability. (panabee.com)
The FDA extended the review period for DCCR to March 27, 2025, suggesting potential regulatory hurdles and delaying potential revenue. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SLNO

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs